Interesting Images68Ga-PSMA PET/CT and 18F-FDG PET/CT in Renal Cell CarcinomaChen, Ew-Jun MSc∗,†; Tan, Teik Hin MD∗,†; Chew, Ming Tsuey PhD∗; Chye, Ping Ching MD‡Author Information From the ∗Centre for Biomedical Physics, School of Healthcare and Medical Sciences, Sunway University †Nuclear Medicine Centre ‡Department of Orthopaedic Oncology, Sunway Medical Centre, Petaling Jaya, Malaysia. Received for publication September 28, 2019; revision accepted March 6, 2020. Contribution of author: E.W.C. and T.H.T. drafted the manuscript. All authors read and approved the final manuscript. Conflicts of interest and sources of funding: none declared. Correspondence to: Teik Hin Tan, MD, Nuclear Medicine Centre, Sunway Medical Centre. No. 5 Jalan Lagoon Selatan, Bandar Sunway, 47500 Petaling Jaya, Selangor Darul Ehsan, Malaysia. E-mail: email@example.com. Clinical Nuclear Medicine: July 2020 - Volume 45 - Issue 7 - p e317-e319 doi: 10.1097/RLU.0000000000003053 Buy Metrics Abstract Recent case reports and series have demonstrated the usefulness of 68Ga/18F-PSMA PET/CT in restaging recurrent renal cancer after nephrectomy. We presented a case of a patient with renal mass who had undergone both 18F-FDG and 68Ga-PSMA PET/CT for diagnosis and staging. Concordant tracer uptake in the primary tumor and metastatic lesions was demonstrated by both radiotracers. Final histopathological reports revealed clear cell renal cell carcinoma. Furthermore, unusual left metacarpal bone metastasis was also detected. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.